The Oncology Institute Enrolls Nation's First 2 Patients In Phase 3 Open-Label, Randomized Clinical Trial Of Pirtobrutinib
The Oncology Institute Enrolls Nation's First 2 Patients In Phase 3 Open-Label, Randomized Clinical Trial Of Pirtobrutinib
The Oncology Institute, Inc. (NASDAQ:TOI), today announces the enrollment of two of its patients as the first and second patients dosed in the United States in a phase 3 open-label, randomized study of Pirtobrutinib (LOXO-305) versus Ibrutinib in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314). Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013. If approved, Pirtobrutinib (LOXO-305) aims to have better efficacy than other alternatives currently available. Benefits can include symptom reduction for patients. Eli Lilly and Company serves as the sponsor of this clinical trial.
The Oncology Institute, Inc. (NASDAQ:TOI), today announces the enrollment of two of its patients as the first and second patients dosed in the United States in a phase 3 open-label, randomized study of Pirtobrutinib (LOXO-305) versus Ibrutinib in patients with Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (BRUIN-CLL-314). Pirtobrutinib (LOXO-305) is currently in clinical trial phase, whereas Ibrutinib has been available in the market since 2013. If approved, Pirtobrutinib (LOXO-305) aims to have better efficacy than other alternatives currently available. Benefits can include symptom reduction for patients. Eli Lilly and Company serves as the sponsor of this clinical trial.
亞洲網加利福尼亞州聖克拉拉5月31日電腫瘤研究所公司(納斯達克市場代碼：TOI)今天宣佈，該公司的兩名患者參加了在美國進行的第三階段開放隨機對照研究，即Pirtobrutinib(LOXO-305)和Ibrutinib治療慢性淋巴細胞性白血病/小淋巴細胞性淋巴瘤(Bruin-CLL-314)的首批和第二批患者。Pirtobrutinib(LOXO-305)目前處於臨牀試驗階段，而Ibrutinib自2013年以來一直在市場上銷售。如果獲得批准，Pirtobrutinib(LOXO-305)的目標是具有比現有其他替代品更好的療效。好處可以包括減輕患者的症狀。禮來公司是這項臨牀試驗的贊助商。
譯文內容由第三人軟體翻譯。
風險及免責聲明
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能，分享給你的好友吧